Table Of Contents:

1. Market Context & Strategic Relevance

1.1 Opening Context (Why the market matters)

1.1.1 Why This Market Is Gaining Strategic Attention

1.1.2 Business Decisions This Report Supports

1.2 Scope

1.3 Research & Methodology

2. Executive Summary

2.1 Market Snapshot

2.2 Market Absolute $ Opportunity Assessment & Y-o-Y Analysis, 2022-2035

2.3 Market Size & Forecast, By Segmentation, 2022-2035

2.3.1 Market Size by Product

2.3.2 Market Size by Indication

2.3.3 Market Size by Target Receptor

2.3.4 Market Size by End User

2.4 Market Share & Bps Analysis by Region, 2025

2.5 Industry Growth Scenarios - Conservative, Likely & Optimistic

2.6 Industry CxO's Perspective

3. Market Overview

3.1 Market Dynamics

3.1.1 Drivers

3.1.2 Restraints

3.1.3 Opportunities

3.1.4 Key Market Trends

3.2 Industry PESTLE Analysis

3.3 Key Industry Forces (Porter's) Impacting Market Growth

3.4 Industry Supply Chain Analysis

3.4.1 Radioisotope & Precursor Suppliers

3.4.2 Radioligand Therapy Manufacturers

3.4.3 Radiopharmacies & Distributors

3.4.4 Hospitals & Nuclear Medicine End Users

3.5 Industry Life Cycle Assessment

4. STATISTICAL INSIGHTS & TRENDS REPORTING (2025)

4.1 Radioligand Therapy Treatment & Capacity Trends (2025)

4.1.1 Global Radioligand Therapy Treatment Volume Statistics

4.1.2 Radioligand Therapy Manufacturing Capacity Expansion Trends

4.1.3 Radiopharmaceutical Production & Supply Capacity Trends

4.1.4 Regional Radioligand Therapy Treatment Capacity Assessment

4.2 Radioligand Therapy Clinical & Patient Treatment Trends (2025)

4.2.1 Global Radioligand Therapy Patient Treatment Statistics

4.2.2 Clinical Trial Enrollment & Treatment Pipeline Trends

4.2.3 Patient Eligibility & Treatment-Line Trends

4.2.4 Treatment Cycle, Dosage & Administration Trends

4.3 Radioligand Supply Chain & Radioisotope Trends (2025)

4.3.1 Medical Radioisotope Production & Availability Trends

4.3.2 Lutetium-177 & Actinium-225 Supply Trends

4.3.3 Radioisotope Procurement, Transportation & Logistics Trends

4.3.4 Radioligand Manufacturing, Processing & Quality-Control Trends

4.4 Regulatory, Clinical & Commercialization Trends (2025)

4.4.1 Radioligand Therapy Drug Approval & Regulatory Activity

4.4.2 Clinical Guideline & Treatment Protocol Development Trends

4.4.3 Radiopharmaceutical Safety & Radiation-Protection Trends

4.4.4 Radioligand Therapy Product Launch & Commercialization Trends

4.5 Technology, Investment & Innovation Trends (2025)

4.5.1 AI & Computational Imaging Integration in Radioligand Therapy

4.5.2 Target Discovery, Biomarker & Precision Oncology Innovation Trends

4.5.3 Venture Investment, Funding & Strategic Partnership Trends

4.5.4 Radioligand Manufacturing Cost Optimization & Technology Commercialization Trends

5. Radioligand Therapy Market Segmental Analysis & Forecast, By Product, 2022-2035, Value (USD Billion)

5.1 Introduction

5.2 Lutetium-177 Vipivotide Tetraxetan

5.2.1 Key Trends

5.2.2 Market Size & Forecast, 2022-2035

5.3 Lutetium-177 Dotatate

5.4 Radium-223 Dichloride

5.5 Iobenguane I-131

5.6 Others

6. Radioligand Therapy Market Segmental Analysis & Forecast, By Indication, 2022-2035, Value (USD Billion)

6.1 Introduction

6.2 Prostate Cancer

6.2.1 Key Trends

6.2.2 Market Size & Forecast, 2022-2035

6.3 Neuroendocrine Tumors

6.4 Thyroid Cancer

6.5 Others

7. Radioligand Therapy Market Segmental Analysis & Forecast, By Target Receptor, 2022-2035, Value (USD Billion)

7.1 Introduction

7.2 PSMA

7.2.1 Key Trends

7.2.2 Market Size & Forecast, 2022-2035

7.3 SSTR

7.4 Others

8. Radioligand Therapy Market Segmental Analysis & Forecast, By End User, 2022-2035, Value (USD Billion)

8.1 Introduction

8.2 Hospitals & Specialized Cancer Centers

8.2.1 Key Trends

8.2.2 Market Size & Forecast, 2022-2035

8.3 Diagnostic & Imaging Centers

8.4 Academic & Research Institutes

9. Radioligand Therapy Market Segmental Analysis & Forecast by Region, 2022-2035, Value (USD Billion)

9.1 Introduction

9.2 North America

9.2.1 Key Trends

9.2.2 Radioligand Therapy Market Size & Forecast, By Product, 2022-2035

9.2.3 Radioligand Therapy Market Size & Forecast, By Indication, 2022-2035

9.2.4 Radioligand Therapy Market Size & Forecast, By Target Receptor, 2022-2035

9.2.5 Radioligand Therapy Market Size & Forecast, By End User, 2022-2035

9.2.6 Radioligand Therapy Market Size & Forecast, By Country, 2022-2035

9.2.6.1 USA

9.2.6.2 Canada

9.3 Europe

9.3.1 Key Trends

9.3.2 Radioligand Therapy Market Size & Forecast, By Product, 2022-2035

9.3.3 Radioligand Therapy Market Size & Forecast, By Indication, 2022-2035

9.3.4 Radioligand Therapy Market Size & Forecast, By Target Receptor, 2022-2035

9.3.5 Radioligand Therapy Market Size & Forecast, By End User, 2022-2035

9.3.6 Radioligand Therapy Market Size & Forecast, By Country, 2022-2035

9.3.6.1 Germany

9.3.6.2 UK

9.3.6.3 France

9.3.6.4 Italy

9.3.6.5 Spain

9.3.6.6 Russia

9.3.6.7 Poland

9.3.6.8 Rest of Europe

9.4 Asia-Pacific

9.4.1 Key Trends

9.4.2 Radioligand Therapy Market Size & Forecast, By Product, 2022-2035

9.4.3 Radioligand Therapy Market Size & Forecast, By Indication, 2022-2035

9.4.4 Radioligand Therapy Market Size & Forecast, By Target Receptor, 2022-2035

9.4.5 Radioligand Therapy Market Size & Forecast, By End User, 2022-2035

9.4.6 Radioligand Therapy Market Size & Forecast, By Country, 2022-2035

9.4.6.1 China

9.4.6.2 India

9.4.6.3 Japan

9.4.6.4 South Korea

9.4.6.5 Australia

9.4.6.6 ASEAN Countries

9.4.6.7 Rest of Asia-Pacific

9.5 Latin America

9.5.1 Key Trends

9.5.2 Radioligand Therapy Market Size & Forecast, By Product, 2022-2035

9.5.3 Radioligand Therapy Market Size & Forecast, By Indication, 2022-2035

9.5.4 Radioligand Therapy Market Size & Forecast, By Target Receptor, 2022-2035

9.5.5 Radioligand Therapy Market Size & Forecast, By End User, 2022-2035

9.5.6 Radioligand Therapy Market Size & Forecast, By Country, 2022-2035

9.5.6.1 Brazil

9.5.6.2 Argentina

9.5.6.3 Mexico

9.5.6.4 Colombia

9.5.6.5 Rest of Latin America

9.6 Middle East & Africa

9.6.1 Key Trends

9.6.2 Radioligand Therapy Market Size & Forecast, By Product, 2022-2035

9.6.3 Radioligand Therapy Market Size & Forecast, By Indication, 2022-2035

9.6.4 Radioligand Therapy Market Size & Forecast, By Target Receptor, 2022-2035

9.6.5 Radioligand Therapy Market Size & Forecast, By End User, 2022-2035

9.6.6 Radioligand Therapy Market Size & Forecast, By Country, 2022-2035

9.6.6.1 UAE

9.6.6.2 Saudi Arabia

9.6.6.3 Qatar

9.6.6.4 South Africa

9.6.6.5 Rest of Middle East & Africa

10. Competitive Landscape

10.1 Key Players' Positioning

10.2 Competitive Developments

10.2.1 Year-Wise Strategies & Development, 2022-2025

10.3 Market Share Analysis, 2025

10.4 Product/Service & Application Benchmarking

10.4.1 Product/Service Specifications & Features by Key Players

10.4.2 Product/Service Heatmap by Key Players

10.4.3 Application Heatmap by Key Players

10.5 Industry Start-Up & Innovation Landscape

10.6 Key Company Profiles

10.6.1 Novartis AG

10.6.1.1 Company Overview & Snapshot

10.6.1.2 Product/Service Portfolio

10.6.1.3 Key Company Financials

10.6.1.4 Geographical Presence

10.6.1.5 SWOT Analysis

10.6.2 Eli Lilly and Company

10.6.3 Bayer AG

10.6.4 AstraZeneca plc

10.6.5 Bristol-Myers Squibb Company

10.6.6 Lantheus Holdings, Inc.

10.6.7 Curium Pharma

10.6.8 Telix Pharmaceuticals Limited

10.6.9 ITM Isotope Technologies Munich SE

10.6.10 Sanofi

10.6.11 Orano Med

10.6.12 RadioMedix, Inc.

10.6.13 Clarity Pharmaceuticals

10.6.14 Ariceum Therapeutics GmbH

10.6.15 Perspective Therapeutics, Inc.

10.6.16 Evergreen Theragnostics, Inc.

10.6.17 Radiopharm Theranostics Limited

10.6.18 Convergent Therapeutics, Inc.

10.6.19 AdvanCell Pty Ltd.

10.6.20 Molecular Partners AG

11. Analyst Recommendations

11.1 SNS Insider Opportunity Map

11.2 Industry Low-Hanging Fruit Assessment

11.3 Market Entry & Growth Strategy

11.4 Analyst Viewpoint & Suggestions on Market Growth

12. Assumptions

13. Disclaimer

14. Appendix

14.1 List of Tables

14.2 List of Figures